Skye Bioscience Inc (SKYE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2018 | 12-2017 | 12-2016 | 12-2015 | 12-2014 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -19,194 | -3,094 | -3,178 | -4,841 | -2,734 |
| Depreciation Amortization | 60 | 38 | 67 | 595 | 2 |
| Accounts payable and accrued liabilities | -85 | -174 | 149 | -274 | 407 |
| Other Working Capital | 100 | -324 | 41 | -419 | 500 |
| Other Operating Activity | 15,176 | 223 | -631 | 1,211 | 70 |
| Operating Cash Flow | $-3,943 | $-3,331 | $-3,553 | $-3,728 | $-1,755 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -4 | -20 | -11 | -2 | -23 |
| Investing Cash Flow | $-4 | $-20 | $-11 | $-2 | $-23 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 2,346 | 500 | N/A | N/A | N/A |
| Common Stock Issued | 3,195 | N/A | N/A | 721 | 1,986 |
| Other Financing Activity | 0 | 3,013 | 408 | 6,023 | 0 |
| Financing Cash Flow | $5,541 | $3,513 | $408 | $6,744 | $1,986 |
| Beginning Cash Position | 264 | 102 | 3,221 | 207 | N/A |
| End Cash Position | 1,858 | 264 | 65 | 3,221 | 207 |
| Net Cash Flow | $1,594 | $162 | $-3,156 | $3,014 | $207 |
| Free Cash Flow | |||||
| Operating Cash Flow | -3,943 | -3,331 | -3,553 | -3,728 | -1,755 |
| Capital Expenditure | -4 | -20 | -11 | -2 | -23 |
| Free Cash Flow | -3,947 | -3,351 | -3,564 | -3,730 | -1,779 |